Clinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPC — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Clinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPC — Stella

Recruiting

Back to Metastatic Prostate Cancer trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

Changzheng hospital, Shanghai, Shanghai Municipality

Key details

Phase

Early testing

Sponsor

Shanghai Changzheng Hospital

Collaborators

Bioray Laboratories

Enrollment target

~3 participants

Started

March 2025

Primary completion

November 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 80 Years

Sex

Male only

Last updated April 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov